

Pulmonary Drugs-Global Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/P6B24C0D95EMEN.html>

Date: May 2018

Pages: 141

Price: US\$ 2,480.00 (Single User License)

ID: P6B24C0D95EMEN

Abstracts

Report Summary

Pulmonary Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Pulmonary Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Pulmonary Drugs 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Pulmonary Drugs worldwide, with company and product introduction, position in the Pulmonary Drugs market

Market status and development trend of Pulmonary Drugs by types and applications

Cost and profit status of Pulmonary Drugs, and marketing status

Market growth drivers and challenges

The report segments the global Pulmonary Drugs market as:

Global Pulmonary Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America

Europe

China

Japan

Rest APAC

Latin America

Global Pulmonary Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Inhaled Corticosteroids (ICS)
Long-Acting Beta2-Agonists (LABA)
Antihistamine
Vasodilators
Short-Acting Beta2-Agonists (SABA)
Anticholinergics
Combination Drugs
MAbs
Enzymes
Antibiotics & Antileukotrienes

Global Pulmonary Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis

Global Pulmonary Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Pulmonary Drugs Sales Volume, Revenue, Price and Gross Margin):

AstraZeneca plc
Bayer AG?
Teva Pharmaceutical Industries Ltd.?
Actelion Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
GlaxoSmithKline plc
Sunovion Pharmaceuticals, Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF PULMONARY DRUGS

- 1.1 Definition of Pulmonary Drugs in This Report
- 1.2 Commercial Types of Pulmonary Drugs
 - 1.2.1 Inhaled Corticosteroids (ICS)
 - 1.2.2 Long-Acting Beta2-Agonists (LABA)
 - 1.2.3 Antihistamine
 - 1.2.4 Vasodilators
 - 1.2.5 Short-Acting Beta2-Agonists (SABA)
 - 1.2.6 Anticholinergics
 - 1.2.7 Combination Drugs
 - 1.2.8 MAbs
 - 1.2.9 Enzymes
 - 1.2.10 Antibiotics & Antileukotrienes
- 1.3 Downstream Application of Pulmonary Drugs
 - 1.3.1 Asthma & COPD
 - 1.3.2 Allergic Rhinitis
 - 1.3.3 Pulmonary Arterial Hypertension
 - 1.3.4 Cystic Fibrosis
- 1.4 Development History of Pulmonary Drugs
- 1.5 Market Status and Trend of Pulmonary Drugs 2013-2023
 - 1.5.1 Global Pulmonary Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Pulmonary Drugs Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Pulmonary Drugs 2013-2017
- 2.2 Sales Market of Pulmonary Drugs by Regions
 - 2.2.1 Sales Volume of Pulmonary Drugs by Regions
 - 2.2.2 Sales Value of Pulmonary Drugs by Regions
- 2.3 Production Market of Pulmonary Drugs by Regions
- 2.4 Global Market Forecast of Pulmonary Drugs 2018-2023
 - 2.4.1 Global Market Forecast of Pulmonary Drugs 2018-2023
 - 2.4.2 Market Forecast of Pulmonary Drugs by Regions 2018-2023

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Pulmonary Drugs by Types
- 3.2 Sales Value of Pulmonary Drugs by Types
- 3.3 Market Forecast of Pulmonary Drugs by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Global Sales Volume of Pulmonary Drugs by Downstream Industry
- 4.2 Global Market Forecast of Pulmonary Drugs by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America Pulmonary Drugs Market Status by Countries
 - 5.1.1 North America Pulmonary Drugs Sales by Countries (2013-2017)
 - 5.1.2 North America Pulmonary Drugs Revenue by Countries (2013-2017)
 - 5.1.3 United States Pulmonary Drugs Market Status (2013-2017)
 - 5.1.4 Canada Pulmonary Drugs Market Status (2013-2017)
 - 5.1.5 Mexico Pulmonary Drugs Market Status (2013-2017)
- 5.2 North America Pulmonary Drugs Market Status by Manufacturers
- 5.3 North America Pulmonary Drugs Market Status by Type (2013-2017)
 - 5.3.1 North America Pulmonary Drugs Sales by Type (2013-2017)
 - 5.3.2 North America Pulmonary Drugs Revenue by Type (2013-2017)
- 5.4 North America Pulmonary Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe Pulmonary Drugs Market Status by Countries
 - 6.1.1 Europe Pulmonary Drugs Sales by Countries (2013-2017)
 - 6.1.2 Europe Pulmonary Drugs Revenue by Countries (2013-2017)
 - 6.1.3 Germany Pulmonary Drugs Market Status (2013-2017)
 - 6.1.4 UK Pulmonary Drugs Market Status (2013-2017)
 - 6.1.5 France Pulmonary Drugs Market Status (2013-2017)
 - 6.1.6 Italy Pulmonary Drugs Market Status (2013-2017)
 - 6.1.7 Russia Pulmonary Drugs Market Status (2013-2017)
 - 6.1.8 Spain Pulmonary Drugs Market Status (2013-2017)
 - 6.1.9 Benelux Pulmonary Drugs Market Status (2013-2017)

- 6.2 Europe Pulmonary Drugs Market Status by Manufacturers
- 6.3 Europe Pulmonary Drugs Market Status by Type (2013-2017)
 - 6.3.1 Europe Pulmonary Drugs Sales by Type (2013-2017)
 - 6.3.2 Europe Pulmonary Drugs Revenue by Type (2013-2017)
- 6.4 Europe Pulmonary Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific Pulmonary Drugs Market Status by Countries
 - 7.1.1 Asia Pacific Pulmonary Drugs Sales by Countries (2013-2017)
 - 7.1.2 Asia Pacific Pulmonary Drugs Revenue by Countries (2013-2017)
 - 7.1.3 China Pulmonary Drugs Market Status (2013-2017)
 - 7.1.4 Japan Pulmonary Drugs Market Status (2013-2017)
 - 7.1.5 India Pulmonary Drugs Market Status (2013-2017)
 - 7.1.6 Southeast Asia Pulmonary Drugs Market Status (2013-2017)
 - 7.1.7 Australia Pulmonary Drugs Market Status (2013-2017)
- 7.2 Asia Pacific Pulmonary Drugs Market Status by Manufacturers
- 7.3 Asia Pacific Pulmonary Drugs Market Status by Type (2013-2017)
 - 7.3.1 Asia Pacific Pulmonary Drugs Sales by Type (2013-2017)
 - 7.3.2 Asia Pacific Pulmonary Drugs Revenue by Type (2013-2017)
- 7.4 Asia Pacific Pulmonary Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America Pulmonary Drugs Market Status by Countries
 - 8.1.1 Latin America Pulmonary Drugs Sales by Countries (2013-2017)
 - 8.1.2 Latin America Pulmonary Drugs Revenue by Countries (2013-2017)
 - 8.1.3 Brazil Pulmonary Drugs Market Status (2013-2017)
 - 8.1.4 Argentina Pulmonary Drugs Market Status (2013-2017)
 - 8.1.5 Colombia Pulmonary Drugs Market Status (2013-2017)
- 8.2 Latin America Pulmonary Drugs Market Status by Manufacturers
- 8.3 Latin America Pulmonary Drugs Market Status by Type (2013-2017)
 - 8.3.1 Latin America Pulmonary Drugs Sales by Type (2013-2017)
 - 8.3.2 Latin America Pulmonary Drugs Revenue by Type (2013-2017)
- 8.4 Latin America Pulmonary Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 9.1 Middle East and Africa Pulmonary Drugs Market Status by Countries
 - 9.1.1 Middle East and Africa Pulmonary Drugs Sales by Countries (2013-2017)
 - 9.1.2 Middle East and Africa Pulmonary Drugs Revenue by Countries (2013-2017)
 - 9.1.3 Middle East Pulmonary Drugs Market Status (2013-2017)
 - 9.1.4 Africa Pulmonary Drugs Market Status (2013-2017)
- 9.2 Middle East and Africa Pulmonary Drugs Market Status by Manufacturers
- 9.3 Middle East and Africa Pulmonary Drugs Market Status by Type (2013-2017)
 - 9.3.1 Middle East and Africa Pulmonary Drugs Sales by Type (2013-2017)
 - 9.3.2 Middle East and Africa Pulmonary Drugs Revenue by Type (2013-2017)
- 9.4 Middle East and Africa Pulmonary Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF PULMONARY DRUGS

- 10.1 Global Economy Situation and Trend Overview
- 10.2 Pulmonary Drugs Downstream Industry Situation and Trend Overview

CHAPTER 11 PULMONARY DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 11.1 Production Volume of Pulmonary Drugs by Major Manufacturers
- 11.2 Production Value of Pulmonary Drugs by Major Manufacturers
- 11.3 Basic Information of Pulmonary Drugs by Major Manufacturers
 - 11.3.1 Headquarters Location and Established Time of Pulmonary Drugs Major Manufacturer
 - 11.3.2 Employees and Revenue Level of Pulmonary Drugs Major Manufacturer
- 11.4 Market Competition News and Trend
 - 11.4.1 Merger, Consolidation or Acquisition News
 - 11.4.2 Investment or Disinvestment News
 - 11.4.3 New Product Development and Launch

CHAPTER 12 PULMONARY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 12.1 AstraZeneca plc
 - 12.1.1 Company profile

- 12.1.2 Representative Pulmonary Drugs Product
- 12.1.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca plc
- 12.2 Bayer AG?
 - 12.2.1 Company profile
 - 12.2.2 Representative Pulmonary Drugs Product
 - 12.2.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Bayer AG?
- 12.3 Teva Pharmaceutical Industries Ltd.?
 - 12.3.1 Company profile
 - 12.3.2 Representative Pulmonary Drugs Product
 - 12.3.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Ltd.?
- 12.4 Actelion Pharmaceuticals, Inc.
 - 12.4.1 Company profile
 - 12.4.2 Representative Pulmonary Drugs Product
 - 12.4.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals, Inc.
- 12.5 Boehringer Ingelheim GmbH
 - 12.5.1 Company profile
 - 12.5.2 Representative Pulmonary Drugs Product
 - 12.5.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH
- 12.6 F. Hoffmann-La Roche Ltd.
 - 12.6.1 Company profile
 - 12.6.2 Representative Pulmonary Drugs Product
 - 12.6.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
- 12.7 Merck & Co., Inc.
 - 12.7.1 Company profile
 - 12.7.2 Representative Pulmonary Drugs Product
 - 12.7.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
- 12.8 Novartis AG
 - 12.8.1 Company profile
 - 12.8.2 Representative Pulmonary Drugs Product
 - 12.8.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Novartis AG
- 12.9 GlaxoSmithKline plc
 - 12.9.1 Company profile
 - 12.9.2 Representative Pulmonary Drugs Product
 - 12.9.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc

12.10 Sunovion Pharmaceuticals, Inc.

12.10.1 Company profile

12.10.2 Representative Pulmonary Drugs Product

12.10.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Sunovion Pharmaceuticals, Inc.

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PULMONARY DRUGS

13.1 Industry Chain of Pulmonary Drugs

13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF PULMONARY DRUGS

14.1 Cost Structure Analysis of Pulmonary Drugs

14.2 Raw Materials Cost Analysis of Pulmonary Drugs

14.3 Labor Cost Analysis of Pulmonary Drugs

14.4 Manufacturing Expenses Analysis of Pulmonary Drugs

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

16.1 Methodology/Research Approach

16.1.1 Research Programs/Design

16.1.2 Market Size Estimation

16.1.3 Market Breakdown and Data Triangulation

16.2 Data Source

16.2.1 Secondary Sources

16.2.2 Primary Sources

16.3 Reference

I would like to order

Product name: Pulmonary Drugs-Global Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/P6B24C0D95EMEN.html>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P6B24C0D95EMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970